Unichem Laboratories Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
860.70 -20.90 (-2.37%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
850
Today’s High
908
52 Week Low
401.1
52 Week High
949.85
860.00 -21.35 (-2.42%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
850
Today’s High
892
52 Week Low
400.55
52 Week High
937.95
Unichem Laboratories Analysis
Risk Meter
- 40% Low risk
- 40% Moderate risk
- 40% Balanced Risk
- 40% High risk
- 40% Extreme risk
Unichem Laboratories News
Stock market today: Experts recommend five stocks to buy or sell on Wednesday
5 min read . 23 Oct 2024Unichem Laboratories Q1 results : profit at ₹9.26Cr, Revenue increased by 5.49% YoY
1 min read . 09 Aug 2024Unichem Laboratories Q3 FY24 results: profit at ₹83.99Cr, Revenue increased by 43.6% YoY
1 min read . 07 Feb 2024Unichem Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1704.89
- Selling/ General/ Admin Expenses Total
- 393.06
- Depreciation/ Amortization
- 113.24
- Other Operating Expenses Total
- 546.96
- Total Operating Expense
- 1778.72
- Operating Income
- -73.83
- Net Income Before Taxes
- -61.67
- Net Income
- -70.47
- Diluted Normalized EPS
- -4.69
- Period
- 2024
- Total Assets
- 3169.34
- Total Liabilities
- 806.93
- Total Equity
- 2362.42
- Tangible Book Valueper Share Common Eq
- 335.32
- Period
- 2024
- Cashfrom Operating Activities
- 16.69
- Cashfrom Investing Activities
- 50.4
- Cashfrom Financing Activities
- -106.31
- Net Changein Cash
- -32.84
- Period
- 2023
- Total Revenue
- 1343.02
- Selling/ General/ Admin Expenses Total
- 711.99
- Depreciation/ Amortization
- 113.44
- Total Operating Expense
- 1535.57
- Operating Income
- -192.54
- Net Income Before Taxes
- -176.36
- Net Income
- -202.23
- Diluted Normalized EPS
- -25.43
- Period
- 2023
- Total Assets
- 3193.05
- Total Liabilities
- 757.74
- Total Equity
- 2435.3
- Tangible Book Valueper Share Common Eq
- 345.68
- Period
- 2023
- Cashfrom Operating Activities
- -48.71
- Cashfrom Investing Activities
- 202.81
- Cashfrom Financing Activities
- -81.3
- Net Changein Cash
- 74.56
- Period
- 2022
- Total Revenue
- 1269.83
- Selling/ General/ Admin Expenses Total
- 670.98
- Depreciation/ Amortization
- 91.17
- Total Operating Expense
- 1283.1
- Operating Income
- -13.27
- Net Income Before Taxes
- 21.97
- Net Income
- 33.06
- Diluted Normalized EPS
- 4.92
- Period
- 2022
- Total Assets
- 3318.77
- Total Liabilities
- 700.36
- Total Equity
- 2618.41
- Tangible Book Valueper Share Common Eq
- 371.68
- Period
- 2022
- Cashfrom Operating Activities
- -259.61
- Cashfrom Investing Activities
- 102.4
- Cashfrom Financing Activities
- 191.23
- Net Changein Cash
- 31.74
- Period
- 2021
- Total Revenue
- 1235.14
- Selling/ General/ Admin Expenses Total
- 673.25
- Depreciation/ Amortization
- 84.36
- Total Operating Expense
- 1227.86
- Operating Income
- 7.28
- Net Income Before Taxes
- 51.48
- Net Income
- 34.32
- Diluted Normalized EPS
- 4.92
- Period
- 2021
- Total Assets
- 3125.71
- Total Liabilities
- 568.88
- Total Equity
- 2556.83
- Tangible Book Valueper Share Common Eq
- 362.94
- Period
- 2021
- Cashfrom Operating Activities
- 40.69
- Cashfrom Investing Activities
- -73.56
- Cashfrom Financing Activities
- -121.19
- Net Changein Cash
- -154.06
- Period
- 2020
- Total Revenue
- 1103.71
- Selling/ General/ Admin Expenses Total
- 670.21
- Depreciation/ Amortization
- 80.89
- Total Operating Expense
- 1234.73
- Operating Income
- -131.02
- Net Income Before Taxes
- -48.21
- Net Income
- -60.18
- Diluted Normalized EPS
- -8.34
- Period
- 2020
- Total Assets
- 3144.74
- Total Liabilities
- 613.38
- Total Equity
- 2531.35
- Tangible Book Valueper Share Common Eq
- 359.32
- Period
- 2020
- Cashfrom Operating Activities
- 132.68
- Cashfrom Investing Activities
- -35.91
- Cashfrom Financing Activities
- -62.3
- Net Changein Cash
- 34.47
- Period
- 2019
- Total Revenue
- 1180.05
- Selling/ General/ Admin Expenses Total
- 705.2
- Depreciation/ Amortization
- 67.37
- Total Operating Expense
- 1321.81
- Operating Income
- -141.77
- Net Income Before Taxes
- -59.91
- Net Income
- -23.8
- Diluted Normalized EPS
- -2.27
- Period
- 2019
- Total Assets
- 3149.61
- Total Liabilities
- 529.7
- Total Equity
- 2619.91
- Tangible Book Valueper Share Common Eq
- 371.98
- Period
- 2019
- Cashfrom Operating Activities
- -327.77
- Cashfrom Investing Activities
- -286.01
- Cashfrom Financing Activities
- -2.42
- Net Changein Cash
- -616.19
- Period
- 2018
- Total Revenue
- 814.98
- Selling/ General/ Admin Expenses Total
- 521.39
- Depreciation/ Amortization
- 50.51
- Total Operating Expense
- 993.15
- Operating Income
- -178.16
- Net Income Before Taxes
- -129.76
- Net Income
- 2544.91
- Diluted Normalized EPS
- -14.37
- Period
- 2018
- Total Assets
- 3193.67
- Total Liabilities
- 513.58
- Total Equity
- 2680.08
- Tangible Book Valueper Share Common Eq
- 380.75
- Period
- 2018
- Cashfrom Operating Activities
- -112.34
- Cashfrom Investing Activities
- 1648.33
- Cashfrom Financing Activities
- -881.13
- Net Changein Cash
- 654.86
- Period
- 2024-09-30
- Total Revenue
- 462.16
- Selling/ General/ Admin Expenses Total
- 98.81
- Depreciation/ Amortization
- 28.54
- Other Operating Expenses Total
- 131.34
- Total Operating Expense
- 433.17
- Operating Income
- 28.99
- Net Income Before Taxes
- 32.99
- Net Income
- 30.49
- Diluted Normalized EPS
- 4.32
- Period
- 2024-09-30
- Total Assets
- 3310.96
- Total Liabilities
- 910.31
- Total Equity
- 2400.65
- Tangible Book Valueper Share Common Eq
- 340.75
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 44.83
- Cashfrom Investing Activities
- -46.45
- Cashfrom Financing Activities
- 37.87
- Net Changein Cash
- 36.87
- Period
- 2024-06-30
- Total Revenue
- 446.43
- Selling/ General/ Admin Expenses Total
- 98.49
- Depreciation/ Amortization
- 28.33
- Other Operating Expenses Total
- 143.87
- Total Operating Expense
- 431.26
- Operating Income
- 15.17
- Net Income Before Taxes
- 15
- Net Income
- 9.26
- Diluted Normalized EPS
- 1.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 431.7
- Selling/ General/ Admin Expenses Total
- 99.42
- Depreciation/ Amortization
- 27.16
- Other Operating Expenses Total
- 140.04
- Total Operating Expense
- 559.13
- Operating Income
- -127.43
- Net Income Before Taxes
- -125.87
- Net Income
- -129.31
- Diluted Normalized EPS
- -6.77
- Period
- 2024-03-31
- Total Assets
- 3169.34
- Total Liabilities
- 806.93
- Total Equity
- 2362.42
- Tangible Book Valueper Share Common Eq
- 335.32
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 16.69
- Cashfrom Investing Activities
- 50.4
- Cashfrom Financing Activities
- -106.31
- Net Changein Cash
- -32.84
- Period
- 2023-12-31
- Total Revenue
- 434.38
- Selling/ General/ Admin Expenses Total
- 98.11
- Depreciation/ Amortization
- 27.86
- Other Operating Expenses Total
- 131.66
- Total Operating Expense
- 359.33
- Operating Income
- 75.05
- Net Income Before Taxes
- 83.97
- Net Income
- 83.99
- Diluted Normalized EPS
- 5.65
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 415.63
- Selling/ General/ Admin Expenses Total
- 96.72
- Depreciation/ Amortization
- 29.45
- Other Operating Expenses Total
- 147.34
- Total Operating Expense
- 436.32
- Operating Income
- -20.69
- Net Income Before Taxes
- -21.88
- Net Income
- -24.49
- Diluted Normalized EPS
- -3.48
- Period
- 2023-09-30
- Total Assets
- 3069.93
- Total Liabilities
- 661.92
- Total Equity
- 2408.01
- Tangible Book Valueper Share Common Eq
- 341.8
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -77.58
- Cashfrom Investing Activities
- -8.79
- Cashfrom Financing Activities
- -36.67
- Net Changein Cash
- -120.61
- Period
- 2023-06-30
- Total Revenue
- 423.19
- Selling/ General/ Admin Expenses Total
- 98.81
- Depreciation/ Amortization
- 28.77
- Other Operating Expenses Total
- 127.92
- Total Operating Expense
- 423.94
- Operating Income
- -0.75
- Net Income Before Taxes
- 2.12
- Net Income
- -0.67
- Diluted Normalized EPS
- -0.09
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 402.1
- Selling/ General/ Admin Expenses Total
- 88.73
- Depreciation/ Amortization
- 29.68
- Other Operating Expenses Total
- 121.84
- Total Operating Expense
- 448.84
- Operating Income
- -46.74
- Net Income Before Taxes
- -47.16
- Net Income
- -44.27
- Diluted Normalized EPS
- -3.03
- Period
- 2023-03-31
- Total Assets
- 3193.05
- Total Liabilities
- 757.74
- Total Equity
- 2435.3
- Tangible Book Valueper Share Common Eq
- 345.68
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -48.71
- Cashfrom Investing Activities
- 202.81
- Cashfrom Financing Activities
- -81.3
- Net Changein Cash
- 74.56
- Period
- 2022-12-31
- Total Revenue
- 302.5
- Selling/ General/ Admin Expenses Total
- 90.57
- Depreciation/ Amortization
- 30.78
- Other Operating Expenses Total
- 116.3
- Total Operating Expense
- 376.04
- Operating Income
- -73.54
- Net Income Before Taxes
- -61.28
- Net Income
- -63.93
- Diluted Normalized EPS
- -9.03
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Unichem Laboratories Technical
Moving Average
SMA
- 5 Day882.13
- 10 Day880.92
- 20 Day844.39
- 50 Day729.94
- 100 Day640.76
- 300 Day588.06
Unichem Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Neuland Laboratories
- 14902
- 37.7
- 0.25
- 16544.75
- 4928
- 19119.1
- Astrazeneca Pharma India
- 6304.95
- -192.55
- -2.96
- 8139.85
- 4050.15
- 15762.38
- Unichem Laboratories
- 860.7
- -20.9
- -2.37
- 949.85
- 401.1
- 6059.82
- Themis Medicare
- 287.6
- 1.2
- 0.42
- 313.65
- 152.65
- 2647.07
- Jagsonpal Pharmaceuticals
- 591.65
- 13.55
- 2.34
- 634.95
- 270.05
- 1564.19
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Neuland Laboratories
- 60.01
- 14.89
- 14.98
- 11.99
- Astrazeneca Pharma India
- 108.05
- 22.81
- 20.1
- 10.27
- Unichem Laboratories
- -
- 2.63
- -2.1
- -3.99
- Themis Medicare
- 60.63
- 6.97
- 18.03
- 14.96
- Jagsonpal Pharmaceuticals
- 66.37
- 8.13
- 13.79
- 9.21
Unichem Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-Nov-24
- Quarterly Results
- 30-Sept-24
- Others
- 08-Aug-24
- Quarterly Results
- 22-May-24
- Audited Results
- 05-Feb-24
- Quarterly Results
- 01-Nov-23
- Quarterly Results
- 14-Jul-23
- Quarterly Results
- 23-May-23
- Audited Results
- 06-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Aug-24
- 28-Jun-24
- AGM
- 24-Mar-24
- 21-Feb-24
- POM
- 25-Sept-23
- 09-Aug-23
- AGM
- 05-May-23
- 03-Apr-23
- POM
- 09-Aug-22
- 28-Jun-22
- AGM
- 31-Jul-21
- 22-Jun-21
- AGM
- 29-May-21
- 27-Apr-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-22
- -
- 01-Aug-22
- 4
- 31-May-21
- -
- 22-Jul-21
- 4